Assessing the value of drugs requires an understanding of the effectiveness and safety of drugs but also their costs. The basis of these assessments by decision-making bodies such as public drug plans is often based on data from clinical trials and ideal research environments rather than 'real world' environments, which poses challenges for payers. We will review the framework of how drug value is typically assessed, challenges in measuring 'real world value' and recommendations for drug plans on how best to ensure they're getting value for money.
Dr. Muhammad Mamdani, PharmD, MA, MPH
Director of the University of Toronto Faculty of Medicine Centre for Machine Learning in Medicine
Dr. Mamdani is a member of the Human Drug Advisory Panel of the Patented Medicine Prices Review Board (PMPRB). Previously, Dr. Mamdani founded the Ontario Drug Policy Research Network (ODPRN), which is among the world’s most impactful collaborations between researchers and drug policy decision-makers. Dr. Mamdani obtained a Doctor of Pharmacy degree (PharmD) from the University of Michigan (Ann Arbor) in 1995 and subsequently completed a fellowship in pharmacoeconomics and outcomes research at the Detroit Medical Center in 1997.
(Click Here for Full Bio)
Wednesday November 18, 2020
9:00-10:00 AM ET
COMPLIMENTARY for current chapter members AND those who join the chapter for 2021 for only $50! (CEBS designees are asked to join the Society in order to join the local chapter)
$25 - Non-members
Registration is now closed. Zoom instructions and calendar invite will be sent out to confirmed registrants.
Continuing Education Credits
CEBS Compliance: The program qualifies for one (1) CEBS Compliance credit.
Visit www.cebs.org/compliance for more information.